Greenwich LifeSciences, Inc. (GLSI)
| Previous Close | 13.99 |
| Open | 13.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 13.69 - 14.32 |
| 52 Week Range | 7.58 - 21.44 |
| Volume | |
| Avg. Volume | 45,587 |
| Market Cap | 179.951M |
| Beta (5Y Monthly) | 3.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.79 |
| Earnings Date | Oct 17, 2024 - Oct 21, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.00 |
Simply Wall St.Insider Stock Buying Reaches US$3.36m On Greenwich LifeSciences
In the last year, multiple insiders have substantially increased their holdings of Greenwich LifeSciences, Inc...
GlobeNewswireGreenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. As previously announced, the Company has partnered with GEICAM, the largest academic breast cancer research network in Spa
- GlobeNewswire
Greenwich LifeSciences Set to Join Russell 2000 Index Again
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, accordin
